2133 related articles for article (PubMed ID: 12544300)
21. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
[TBL] [Abstract][Full Text] [Related]
22. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
23. 3-year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: experience from a tertiary referral center in the United States.
Pavlovich CP; Trock BJ; Sulman A; Wagner AA; Mettee LZ; Su LM
J Urol; 2008 Mar; 179(3):917-21; discussion 921-2. PubMed ID: 18207191
[TBL] [Abstract][Full Text] [Related]
24. The ratio of oleic-to-stearic acid in the prostate predicts biochemical failure after radical prostatectomy for localized prostate cancer.
Kositsawat J; Flanigan RC; Meydani M; Choi YK; Freeman VL
J Urol; 2007 Dec; 178(6):2391-6; discussion 2396. PubMed ID: 17936811
[TBL] [Abstract][Full Text] [Related]
25. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
26. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
[TBL] [Abstract][Full Text] [Related]
27. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
28. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
[TBL] [Abstract][Full Text] [Related]
30. Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
Antenor JA; Roehl KA; Eggener SE; Kundu SD; Han M; Catalona WJ
Urology; 2005 Jul; 66(1):156-60. PubMed ID: 15992903
[TBL] [Abstract][Full Text] [Related]
31. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
[TBL] [Abstract][Full Text] [Related]
32. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
[TBL] [Abstract][Full Text] [Related]
33. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
Winkler MH; Khan FA; Hoh IM; Okeke AA; Sugiono M; McInerney P; Boustead GB; Persad R; Kaisary AV; Gillatt DA
BJU Int; 2004 Apr; 93(6):725-9. PubMed ID: 15049980
[TBL] [Abstract][Full Text] [Related]
34. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
35. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
[TBL] [Abstract][Full Text] [Related]
36. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2001 Aug; 166(2):416-9. PubMed ID: 11458039
[TBL] [Abstract][Full Text] [Related]
37. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
38. Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer.
Ramos CG; Carvalhal GF; Smith DS; Mager DE; Catalona WJ
J Urol; 1999 Apr; 161(4):1212-5. PubMed ID: 10081871
[TBL] [Abstract][Full Text] [Related]
39. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
[TBL] [Abstract][Full Text] [Related]
40. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]